Medline Third Quarter 2026 Results Conference Call - MEDLINE INC

Financial Performance:

• Q3 2026 net sales reached $7.9 billion, a 10% year-over-year increase driven by organic growth; MIM Brand grew 7% while Supply Chain Solutions surged 14%.
• Adjusted EBITDA rose 12% to $1 billion, with margins expanding 10 basis points to 12.2%, aided by an $81 million benefit from IEPA tariff refunds.
• Segment performance: U.S. Acute Care sales grew 12% to $5.5B; U.S. Non-Acute Care grew 6% to $1.9B; International sales rose 8% to $518M.
• Lab and Diagnostics sales increased 14% to $272M; Surgical Solutions grew 8% to $1.7B; Frontline Care grew 4% to $1.7B.
• Supply Chain Solutions adjusted EBITDA margin was 4.4% due to customer mix (new prime vendor contracts) and elevated operating expenses.
• First nine months free cash flow was $1.8 billion; CapEx totaled $348 million, with net leverage improved to 2.5x (down from 2.9x) and cash holdings at $3.6 billion.
• Q3 net income was impacted by $80 million in costs related to the Tracy, CA distribution center fire (partially offset by $100M insurance recognition to date).

Guidance and Future Outlook:

• Raised 2026 full-year organic sales guidance to 10.0–10.5% (previously 9.0–10.0%); reaffirmed Adjusted EBITDA guidance of $3.3–3.4 billion, targeting the midpoint.
• Provided preliminary 2027 framework expecting net sales growth in the high single digits and Adjusted EBITDA growth in the low-to-mid single digits, noting margin pressure from inflation and quality investments.
• Expects to return to Adjusted EBITDA growth exceeding sales growth in 2028 as operational investments mature and cost pressures normalize.
• Plan to implement a significant price increase in Q1 2027 to offset inflationary cost pressures; current pricing strategy focuses on absorbing costs where possible before passing them on.
• Restructuring program launched to achieve $80–90 million in annualized savings by 2027, with $20–30 million in one-time restructuring costs expected in Q4 2026.

Business Segments and Product Lines:

• Supply Chain Solutions remains the primary growth engine, with $2.4 billion in new contracts signed in 2025 now flowing through revenue (65% in 2026).
• Canada expansion launched with a prime vendor partnership with Mohawk MedVac, currently live at five hospitals with full rollout targeted for Q1 2027.
• Infrastructure expansion includes new facilities in Dallas (1.2M sq ft), Southern California (1M sq ft), and Michigan (800k sq ft), plus a new Tracy, CA distribution center expected to open by year-end with automated "auto store" technology.
• Lab and Diagnostics penetration remains consistent at ~30% among prime vendor partners, with conversion rates of 10% in year one and 2–4% annually thereafter.
• Exited the home care bed business (~$60M) following FDA consultation as part of the Global Quality Action Plan to focus on "use and replace" items.

Market and Competitive Landscape:

• Market demand remains robust across acute and non-acute sectors; Medline continues to gain share through surgical kitting and operational efficiency solutions.
• Competitively positioned as a "value player," leveraging total cost of ownership and service reliability rather than price-only competition.
• Non-acute care expected to outpace acute care over the long term due to demographic shifts (aging population), though acute care grew faster in Q3 due to recent contract implementations.
• New prime vendor signings totaling $1 billion are on track for 2026, ensuring continued revenue flow into 2027.

Risks and Challenges:

• Inflationary pressures from the Middle East conflict (diesel, raw materials, finished goods) estimated to impact 2026 earnings by $80 million, assumed to persist at current elevated levels through 2027.
• Near-term margin compression in 2027 due to deliberate investments in capacity, automation, and the Global Quality Action Plan, resulting in EBITDA growth trailing sales growth.
• Potential for further quality-related product exits or remediation costs as the multi-year global quality assessment of 30+ manufacturing sites progresses.
• Regulatory risks associated with the Global Quality Action Plan, though management expects no major unanticipated impacts beyond what is already factored into 2026 guidance.

Management Commentary and Tone:

• Management expressed high confidence in long-term earnings power despite near-term margin headwinds, emphasizing a resilient business model and strong balance sheet.
• CEO Jim Boyle highlighted progress on five strategic pillars: customer signings, Canada expansion, Tracy facility, network capacity, and quality.
• CFO Mike Drazen acknowledged the challenge of navigating elevated input costs while maintaining investment discipline, noting that 2027 growth will be "deliberate" to support long-term capacity.
• Tone was constructive and forward-looking, focusing on the structural advantages of the prime vendor model and the strategic nature of current quality investments.

Analyst Questions and Answers:

• Pricing & Inflation: Confirmed pricing increases occur twice yearly (Jan 1/July 1); the upcoming 2027 price hike will partially offset, not fully cover, COGS inflation, with a strategy to leverage Medline brand conversion for value.
• Margin Mix: Explained that lower Supply Chain Solutions margins in Q3 were driven by higher-than-expected first-year rebates on new signings and increased operating expenses, with a recovery expected as brand conversion matures.
• Capital Allocation: Announced a new $1 billion share repurchase program; management reiterated that investment in the business and M&A remain primary priorities, with buybacks and debt paydown reserved for excess cash.
• Political Environment: Stated that U.S. election outcomes are unlikely to significantly impact patient volume or surgical activity, as demand is driven by healthcare access needs rather than political cycles.
• Quality Exits: Clarified that the home care bed exit was an FDA-driven decision on a capital equipment line, not a broad trend, and the cost is baked into current guidance.

Other Key Points:

• Medline executed a $750 million term loan prepayment in October to improve leverage and move toward investment-grade status.
• The company maintains 80 days of inventory on hand to ensure high service levels and fill rates, investing in infrastructure proactively ahead of growth.
• A new "Global Quality Action Plan" involves third-party assessments of all manufacturing sites, a multi-year effort to strengthen patient safety and product quality systems.
• Q4 2026 earnings guidance will be provided on the next earnings call; no specific 2027 numerical guidance was issued, only a preliminary framework.